Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO
Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) improves moderate-to-severe nail psoriasis, according to new research presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL. The Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis. Patients treated with tildrakizumab demonstrated a significantly higher rate of 75% improvement from baseline […]